NAUT Nautilus Biotechnology, Inc.
NAUT Nautilus Biotechnology, Inc.
Healthcare · Biotechnology
Desk view
Market read
POC $1.93 · VWAP $1.97 · +64.7% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Coverage
1 watchlist
NAUT Price Structure
Loading timeframes…
Peers
Every watchlist NAUT belongs to, members best 30-day change first — NAUT highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@biotech-capital-cycle
Reported the quarter ending 2026-06-30: revenue $190000, diluted EPS -$0.11, net income -$14M (SEC filing). Across the print the stock moved -37.3% (close before → first close after).
full note →Against street estimates
How NAUT's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. A consensus out of line with the name's earlier estimates (opposite sign to all of them and over 3x their size) is not graded. EPS only.
Recent news
Headlines about NAUT from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 3 days ago · Oct 20
- Nautilus Biotechnology: NAUT Stock Price Quote & News | Robinhood
- NAUT Stock Price, News & Analysis | Nautilus Biotechnolgy
- Nautilus Biotechnology sets Q3 2026 earnings for Oct. 27 | NAUT Stock News
- NAUT Stock Quote Price and Forecast | CNN
- Nautilus Biotechnology Q3 2026 Earnings Date and Estimates
“On or before” marks an article that arrived without a publish date — the date shown is when the desk pulled it, so the article is at least that old.
NAUT research tape
19 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.